- Home
- BVN vs AXSM Comparison
BVN vs AXSM Comparison
Compare BVN & AXSM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BVN | AXSM |
|---|---|---|
| Founded | 1953 | 2012 |
| Country | Peru | United States |
| Employees | N/A | N/A |
| Industry | Metal Mining | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.4B | 7.4B |
| IPO Year | 1996 | 2015 |
Fundamental Metrics
Financial Performance| Metric | BVN | AXSM |
|---|---|---|
| Price | $29.58 | $152.16 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 20 |
| Target Price | $27.00 | ★ $176.00 |
| AVG Volume (30 Days) | ★ 1.7M | 468.3K |
| Earning Date | 10-30-2025 | 11-03-2025 |
| Dividend Yield | ★ 0.99% | N/A |
| EPS Growth | ★ 20.28 | N/A |
| EPS | ★ 1.70 | N/A |
| Revenue | ★ $1,407,837,000.00 | $561,263,000.00 |
| Revenue This Year | $28.79 | $66.40 |
| Revenue Next Year | $14.32 | $56.13 |
| P/E Ratio | $17.22 | ★ N/A |
| Revenue Growth | 26.97 | ★ 65.83 |
| 52 Week Low | $11.50 | $75.56 |
| 52 Week High | $29.88 | $158.57 |
Technical Indicators
Market Signals| Indicator | BVN | AXSM |
|---|---|---|
| Relative Strength Index (RSI) | 75.04 | 58.25 |
| Support Level | $27.71 | $152.41 |
| Resistance Level | $29.88 | $158.56 |
| Average True Range (ATR) | 1.02 | 4.13 |
| MACD | 0.18 | 0.08 |
| Stochastic Oscillator | 91.08 | 55.41 |
Price Performance
Historical ComparisonAbout BVN Buenaventura Mining Company Inc.
Compania de Minas Buenaventura SAA is a Peruvian precious metals-producing company with experience in mine exploration, development, construction, and operation.
About AXSM Axsome Therapeutics Inc.
Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which there are limited treatment options. Its pipeline products includes AXS-05, AXS-07, AXS-12, and AXS-14. It manages its business as one operating segment and reporting unit, which is the business of developing and delivering novel therapies for the management of CNS disorders.